MARKET DEFINITION

Neurogenetics is a new field of scientific research that uses recent advances in genome sequencing zto better understand the cause of brain and nerve disorders. Depending on the diagnosis, genetic testing for neurogenetic degenerative diseases may be useful. While the genetic underpinnings of some neurological disorders are clear, those of others are not. Some of the more prevalent neurogenetic disorders, including Parkinson's disease and Alzheimer's disease, have subgroups with a known genetic basis, whilst other cases' causes are unknown.

MARKET DYNAMICS

The main factors driving the need for neurogenetic testing are the rising incidence of neurological disorders, public awareness of genetic screening, the accessibility of cutting-edge diagnostic techniques, and the expansion of life science research and development. In DNA sequencing, numerous technological developments are taking place. Next-generation sequencing is the technique currently employed for DNA sequencing. The prevalence of different neurological illnesses is another factor. A WHO research states that the Western Pacific region contributes 10% of the worldwide burden of neurological disorders, followed by the European region with 11.2%. A study found a 39% increase in the number of deaths brought on by neurological disorders over the previous 30 years. Furthermore, rising awareness and increased R & D spending by key players on developing new technologies are anticipated to create lucrative opportunities.

REPORT SCOPE  

The report titled “Global Neurogenetic Testing Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Neurogenetic Testing market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Neurogenetic Testing market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Neurogenetic Testing Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW  

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION  

The Global Neurogenetic Testing Market is segmented based on Technique, end-user, and region. Based on technique, the market has been segmented into MRI, Next generation sequencing, Multiplex ligation-dependent probe amplification (MLPA), Fragment analysis PCR, and Others, whereas based on end-user, the market comprises hospitals, specialty clinics, research institutes, diagnostics laboratories, and others.

COMPETITION LANDSCAPE  

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Neurogenetic Testing market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Neurogenetic Testing market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Neurogenetic Testing market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Neurogenetic Testing industry in the past three years.

Key players in the Global Neurogenetic Testing Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• Neurogene Inc.
• Pacific Biosciences of California Inc.
• Victorian Clinical Genetics Services
• MedGenome
• Blueprint Genetics Oy
• Laboratory Corporation of America
• Apic Bio Inc.
• Lysosomal Therapeutics Inc.
• Seelos Therapeutics
• Ovid Therapeutics
• Wernig Laboratory
• Tacitus Therapeutics Inc.

COVID-19 IMPACT ANALYSIS ON GLOBAL NEUROGENETIC TESTING MARKET  

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED  

1. What is the current size of the global Neurogenetic Testing market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Neurogenetic Testing market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:  

• The report offers comprehensive data on the Neurogenetic Testing market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity

Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective

Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Technique Trends
3.2.2. End-user Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Neurogenetic Testing Market
3.6. COVID-19 Impact Assessment in Neurogenetic Testing Market
3.6.1. Impact Assessment on Global Neurogenetic Testing Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4. Global Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
4.1. Global Neurogenetic Testing Market Share, By Technique, 2017 - 2028 (USD Million)
4.1.1. MRI
4.1.2. Next generation sequencing
4.1.3. Multiplex ligation-dependent probe amplification (MLPA)
4.1.4. Fragment analysis PCR
4.1.5. Others

Chapter 5. Global Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
5.1. Global Neurogenetic Testing Market Share, By End-user, 2017 - 2028 (USD Million)
5.1.1. Hospitals
5.1.2. Specialty clinics
5.1.3. Research institutes
5.1.4. Diagnostics laboratories
5.1.5. Others

Chapter 6. Global Neurogenetic Testing Market Overview, By Geography, 2017 - 2028 (USD Million)
6.1. Global Neurogenetic Testing Market Share, By Geography, 2017 - 2028 (USD Million)
6.1.1. Market End-user and Projections, by Countries, 2017 - 2028 (USD Million)
6.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 7. North America Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
7.1. North America Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
7.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
7.1.2. North America Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
7.1.3. North America Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
7.2. North America Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
7.2.1. U.S. Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
7.2.1.1. U.S. Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
7.2.1.2. U.S. Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
7.2.2. Canada Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
7.2.2.1. Canada Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
7.2.2.2. Canada Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
7.2.3. Mexico Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
7.2.3.1. Mexico Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
7.2.3.2. Mexico Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)

Chapter 8. Europe Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
8.1. Europe Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
8.1.2. Europe Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.1.3. Europe Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2. Europe Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
8.2.1. Germany Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.1.1. Germany Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.1.2. Germany Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.2. France Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.2.1. France Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.2.2. France Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.3. UK Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.3.1. UK Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.3.2. UK Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.4. Italy Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.4.1. Italy Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.4.2. Italy Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.5. Spain Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.5.1. Spain Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.5.2. Spain Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.6. NORDIC Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.6.1. NORDIC Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.6.2. NORDIC Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.7. Russia and CIS Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.7.1. Russia and CIS Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.7.2. Russia and CIS Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.8. Rest of Europe Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
8.2.8.1. Rest of Europe Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
8.2.8.2. Rest of Europe Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)

Chapter 9. Asia Pacific Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. Asia Pacific Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
9.1.2. Asia Pacific Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.1.3. Asia Pacific Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2. Asia Pacific Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. India Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. India Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.2.1.2. India Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.2. China Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. China Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.2.2.2. China Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.3. Japan Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. Japan Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.2.3.2. Japan Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.4. ASEAN Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.2.4.1. ASEAN Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.2.4.2. ASEAN Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.5. South Korea Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.2.5.1. South Korea Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.2.5.2. South Korea Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.6. Australia Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.2.6.1. Australia Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.2.6.2. Australia Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.7. Rest of Asia Pacific Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
9.2.7.1. Rest of Asia Pacific Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
9.2.7.2. Rest of Asia Pacific Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)

Chapter 10. South America Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. South America Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
10.1.2. South America Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
10.1.3. South America Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2. South America Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. Brazil Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. Brazil Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
10.2.1.2. Brazil Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.2. Argentina Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. Argentina Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
10.2.2.2. Argentina Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.3. Rest of South America Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Rest of South America Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
10.2.3.2. Rest of South America Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)

Chapter 11. Middle East & Africa Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Middle East & Africa Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
11.1.2. Middle East & Africa Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
11.2. Middle East & Africa Neurogenetic Testing Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. GCC Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. GCC Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
11.2.1.2. GCC Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.2. South Africa Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. South Africa Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
11.2.2.2. South Africa Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.3. Rest of Middle East & Africa Neurogenetic Testing Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Rest of Middle East & Africa Neurogenetic Testing Market Overview, By Technique, 2017 - 2028 (USD Million)
11.2.3.2. Rest of Middle East & Africa Neurogenetic Testing Market Overview, By End-user, 2017 - 2028 (USD Million)

Chapter 12. Competitive Landscape
12.1. Competitive Environment, 2021
12.2. Strategic Framework
12.2.1. Partnership/Collaborations/Agreement
12.2.2. Expansion
12.2.3. Mergers & Acquisitions
12.2.4. New Product Development

Chapter 13. Key Vendor Analysis
13.1. Neurogene Inc.
13.1.1. Business Overview
13.1.2. Product Benchmarking
13.1.3. Financial Data
13.1.4. Strategic Overview
13.1.5. Key Developments
13.1.6. SWOT Analysis
13.2. Pacific Biosciences of California Inc.
13.2.1. Business Overview
13.2.2. Product Benchmarking
13.2.3. Financial Data
13.2.4. Strategic Overview
13.2.5. Key Developments
13.2.6. SWOT Analysis
13.3. Victorian Clinical Genetics Services
13.3.1. Business Overview
13.3.2. Product Benchmarking
13.3.3. Financial Data
13.3.4. Strategic Overview
13.3.5. Key Developments
13.3.6. SWOT Analysis
13.4. MedGenome
13.4.1. Business Overview
13.4.2. Product Benchmarking
13.4.3. Financial Data
13.4.4. Strategic Overview
13.4.5. Key Developments
13.4.6. SWOT Analysis
13.5. Blueprint Genetics Oy
13.5.1. Business Overview
13.5.2. Product Benchmarking
13.5.3. Financial Data
13.5.4. Strategic Overview
13.5.5. Key Developments
13.5.6. SWOT Analysis
13.6. Laboratory Corporation of America
13.6.1. Business Overview
13.6.2. Product Benchmarking
13.6.3. Financial Data
13.6.4. Strategic Overview
13.6.5. Key Developments
13.6.6. SWOT Analysis
13.7. Apic Bio Inc.
13.7.1. Business Overview
13.7.2. Product Benchmarking
13.7.3. Financial Data
13.7.4. Strategic Overview
13.7.5. Key Developments
13.7.6. SWOT Analysis
13.8. Lysosomal Therapeutics Inc.
13.8.1. Business Overview
13.8.2. Product Benchmarking
13.8.3. Financial Data
13.8.4. Strategic Overview
13.8.5. Key Developments
13.8.6. SWOT Analysis
13.9. Seelos Therapeutics
13.9.1. Business Overview
13.9.2. Product Benchmarking
13.9.3. Financial Data
13.9.4. Strategic Overview
13.9.5. Key Developments
13.9.6. SWOT Analysis
13.10. Ovid Therapeutics
13.10.1. Business Overview
13.10.2. Product Benchmarking
13.10.3. Financial Data
13.10.4. Strategic Overview
13.10.5. Key Developments
13.10.6. SWOT Analysis
13.11. Wernig Laboratory
13.11.1. Business Overview
13.11.2. Product Benchmarking
13.11.3. Financial Data
13.11.4. Strategic Overview
13.11.5. Key Developments
13.11.6. SWOT Analysis
13.12. Tacitus Therapeutics Inc.
13.12.1. Business Overview
13.12.2. Product Benchmarking
13.12.3. Financial Data
13.12.4. Strategic Overview
13.12.5. Key Developments
13.12.6. SWOT Analysis

Chapter 14. Future Outlook of the Market
Disclaimer